Life360 Inc (ASX: 360) shares are making a strong start to the week.

The ASX technology stock jumped 11% to $26.22 during Monday’s lunch-hour trade, extending an impressive recent rebound.

Life360 shares have now climbed around 35% over the past month. Even so, the stock remains well below its October peak and is still down roughly 16% over the past 12 months. By comparison, the S&P/ASX 200 Index (ASX: XJO) has gained about 3% over the same period.

So, what sparked today’s rally?

No major announcement, just improving sentiment

Interestingly, there has been no market-sensitive announcement from the company today. Instead, the buying appears to reflect growing confidence among investors and analysts that Life360’s underlying business is continuing to strengthen.

Life360 operates one of the world’s largest family safety platforms, offering location sharing, crash detection, emergency assistance, digital safety features, and device protection through a subscription-based model.

Its business continues to expand as more families join the platform and existing users upgrade to paid memberships.

Brokers are becoming more optimistic

Analyst sentiment around Life360 shares has steadily improved in recent months. TradingView data shows that 12 out of 13 analysts covering Life360 shares in the past three months rate it a buy or strong buy.

The average price target is $31.88, representing a potential 22% gain at current levels. The most bullish forecast sees a 53% upside, while the most pessimistic prediction sits around the current share price.

One reason for the improved sentiment is Life360’s continued growth in annualised recurring revenue (ARR), which gives investors greater visibility over future earnings.

Sustainable profitability, focus on AI

The company has also made significant progress towards sustainable profitability, easing concerns that high-growth technology companies must continually sacrifice earnings to expand.

Another positive is management’s growing focus on artificial intelligence, with AI expected to improve customer engagement, personalise features, and create additional monetisation opportunities over time.

Valuation is another factor. Following the heavy sell-off earlier this year, Life360 shares now trade on a price-to-earnings (P/E) ratio of roughly 27 times.

For a technology company still delivering strong subscriber growth, many investors see that multiple as increasingly attractive.

In other words, while the share price weakened sharply during the first half of 2026, the business itself continued moving in the opposite direction.

A rotation back into growth stocks?

There’s another possible explanation behind today’s move. Life360 shares were one of the hardest-hit ASX technology stocks during the first half of 2026 as investors rotated away from growth companies.

Now, that trend may be reversing. Stocks that have been heavily sold often rebound sharply when sentiment improves, particularly if the underlying business continues delivering strong operational results.

Whether today’s rally marks the beginning of a sustained recovery remains to be seen.

The post Life360 shares just jumped 11%. Here’s what’s driving the rally appeared first on The Motley Fool Australia.

More reading

• Why I think Life360 and Zip shares are strong buys
• Why this analyst rates Life360 shares a buy right now
• 5 ASX growth shares I want in my portfolio in FY27
• 3 reasons to buy the dip on Life360 shares today
• Buy, hold, sell: Life360, Woodside, CSL shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Clarity Pharmaceuticals Ltd (ASX: CU6) were trading more than 10% higher in early trade on Monday after the company said it was going to present data from studies of its prostate cancer detection compound at an esteemed European medical conference.

But what was perhaps more compelling in the company’s announcement was a first person account from a patient who had used the company’s compound and had benefited greatly from it.

New detection methods being developed

Clarity has developed two radiopharmaceutical compounds called 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA which its studies to date show perform well compared with existing detection methods.

The company said it will present various data relating to the compounds at the European Association of Nuclear Medicine (EANM) Annual Congress 2026, which is being held in October in Vienna.

The biotechnology company said regarding the conference:

EANM 2026 Annual Congress is one of the world’s leading nuclear medicine conferences and the acceptance of these abstracts is testament to the strength of the data generated by Clarity’s products and the promising prospects for SAR-bisPSMA to change the paradigm in the diagnosis and treatment of prostate cancer.

The company said one of its trials which will be presented, “demonstrated improved diagnostic performance of 64Cu-SAR-bisPSMA next-day imaging vs. 68Ga-PSMA-11 across all key parameters assessed, including mean number of lesions per participant, total number of lesions, true positive rate and proportion of participants with a positive scan”.

The company will also present data from three client case studies, and said the use of its compound, “changed planned clinical management in all three patients”.

One of the patients, Steve Hunter, also supplied a testimonial.

Compelling first person account

Mr Hunter said he was diagnosed with prostate cancer in 2016, and while his initial treatment was quite successful, blood tests revealed in 2023 that his cancer had returned.

He said:

With SOC PSMA imaging currently available, no lesions were detectable. I was informed by more than one doctor that what I had was a micro-metastatic version of prostate cancer; that is, I had a large number of cancers too small to be detected.

Mr Hunter, himself a medical professional with a history including oncology research, approached Clarity with a view to trying its technology.

He said:

The results were beyond my expectations. Three tumours were found and I underwent targeted external beam radiation. Since then, I have repeated this process with Clarity and (Dr Alan Taylor’s) support a few times to scan, find and subsequently treat the ensuant small number of tumours that arise, with stereotactic radiation therapy. I am so grateful to Clarity in making these scans available. This approach has proven to be highly successful by allowing me to obtain clear information about my disease and defer requiring ADT therapy and all the associated side effects with this treatment.

Clarity shares were trading 14.1% higher at $2.07.  

The post Why is this ASX biotech charging more than 10% higher? appeared first on The Motley Fool Australia.

More reading

• This beaten-down ASX gold stock is jumping on a $300 million deal
• Forget term deposits! I’d buy these two ASX 300 shares instead
• Buy, hold, sell: Wildcat Resources, NAB, Wisetech shares
• Which ASX ETF will pay an eye-popping $18 per share dividend this season?
• What are ASX 200 futures?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Monday has finally brought some relief for Ramelius Resources Ltd (ASX: RMS) shareholders.

After a rough start to 2026, the ASX gold stock is climbing after announcing a $300 million deal to sell its Edna May Gold Hub in Western Australia.

At the time of writing, the Ramelius share price is up 3.81% to $3.00 apiece. By comparison, the S&P/ASX 200 Index(ASX: XJO) is up 0.1% to 8,775 points.

That still leaves the stock down around 28% since the start of the year, although it remains 20% higher over the past 12 months.

Let’s take a closer look at the deal.

Ramelius sells Edna May

According to the release, Ramelius has entered into a binding agreement to sell the Edna May Gold Hub to Forrestania Resources Ltd (ASX: FRS).

Forrestania shares last traded at 42.5 cents before the company was placed in a trading halt.

The deal is worth $300 million upfront, made up of $200 million in cash and $100 million in Forrestania shares.

Ramelius has already received a $20 million deposit, with the rest of the cash and shares payable once the transaction is completed.

Edna May has been part of Ramelius since 2017, when it was acquired from Evolution Mining Ltd (ASX: EVN). Since then, the operation has produced around 760,000 ounces of gold.

However, the mine is not currently producing. It has been on care and maintenance duties from April 2025.

Ramelius managing director Mark Zeptner described the sale as “a logical transaction” for both companies.

Why buyers are returning today

The positive share price reaction suggests investors are happy to see Ramelius unlock value from Edna May.

The company is receiving a sizeable cash payment from an asset that is no longer producing. It also keeps some exposure to Edna May through its Forrestania shareholding.

That could be very useful if Forrestania can get the processing plant running again and build a larger regional gold business around the asset.

Ramelius said it is now focused on the transformation of its Mt Magnet operations and the development of Rebecca-Roe.

What happens next

Although the sale appears to be moving forward, keep in mind that the deal isn’t done just yet.

Forrestania still needs to secure at least $200 million in binding commitments under its proposed equity raising.

And on top of that, its shareholders also need to approve the issue of shares under the agreement.

If those conditions are met, Ramelius expects the transaction to complete in the September quarter of 2026.

The post This beaten-down ASX gold stock is jumping on a $300 million deal appeared first on The Motley Fool Australia.

More reading

• This ASX gold company’s aggressive M&A program continues with $300 million deal
• 5 ASX 200 gold stocks to buy and hold amid the crashing gold price
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today
• 6 ASX shares upgraded by analysts this week

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.